Company Encyclopedia
View More
name
CMBC CAPITAL
01141.HK
CMBC Capital Holdings Limited, an investment holding company, provides loan financing services primarily in Hong Kong. It operates through Securities, Fixed-Income Direct Investment, Other Investment and Financing, Asset Management, Corporate Finance and Advisory, and Others segments. The company offers brokerage, securities margin financing, and securities underwriting/placing services; and invests and trades in fixed-income and equity securities, bonds, and funds, as well as provides money lending and loan financing services. It also provides asset management services; sponsorship, corporate financing, financial advisory, and financial arrangement, as well as client referral services; and futures and option dealing services.
1.776 T
01141.HKMarket value -Rank by Market Cap -/-

Financial Score

24/12/2025 Update
C
Investment Banking and BrokerageIndustry
Industry Ranking26/59
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE6.05%C
    • Profit Margin28.97%A
    • Gross Margin100.00%A
  • Growth ScoreA
    • Revenue YoY9354.38%A
    • Net Profit YoY136.78%A
    • Total Assets YoY25.59%A
    • Net Assets YoY11.96%B
  • Cash ScoreB
    • Cash Flow Margin345.16%C
    • OCF YoY9354.38%A
  • Operating ScoreE
    • Turnover0.07E
  • Debt ScoreD
    • Gearing Ratio68.55%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    New Stock News | Vitality Group's Hong Kong IPO Prospectus Invalidated

    Vibrant Group Holdings Limited (hereinafter referred to as: Vibrant Group) submitted its Hong Kong stock prospectus on April 30, which will expire on October 30 after 6 months. During the submission, China Merchants Securities International and CMBC CAPITAL served as its joint sponsors. According to the previous prospectus, Vibrant Group was founded in 2009, initially starting with the flight dynamic information application "Flight Butler," and later launched "High-speed Rail Butler," gradually developing into a one-stop comprehensive travel platform covering the entire travel chain before, during, and after the trip. As of December 31, 2024, the company has accumulated over 197 million registered users, with paid user loyalty consistently leading the industry. In 2024, revenue surged to RMB 647 million, representing a year-on-year increase, with a three-year compound annual growth rate of 52%

    Zhitong·
    HK
    01141
    -4.29%
    Zhitong·
    HK
    01141
    -4.29%

    New Stock News | Dayi Group's Hong Kong IPO Prospectus Invalidated

    Xi'an Deyi Group Co., Ltd. (abbreviated as Deyi Group) submitted its Hong Kong stock prospectus on April 28, which will expire on October 28 after 6 months. During the submission, CITIC Securities International, Pudong Development Bank International, and CMBC CAPITAL served as its joint sponsors. According to the prospectus, Deyi Group is a global leader and pioneer in innovative radiotherapy solutions, dedicated to building a new generation of intelligent radiotherapy ecosystems. Since its establishment in 2011, the group has developed a comprehensive treatment matrix, which includes multiple solutions that have been approved and/or are in development stages. The group's core product, CybeRay, is the world's first real-time image-guided gamma radiotherapy system, which received approval from the U.S. Food and Drug Administration ("FDA") in March 2021 and from the National Medical Products Administration of China ("NMPA") in July 2022, and is currently in the research and development stage for expanding indications. The group also has a flagship product, TaiChiRT Pro, which is the world's first integrated radiotherapy system for X/gamma rays to receive breakthrough medical device designation from the FDA

    Zhitong·
    HK
    01141
    -4.29%
    Zhitong·
    HK
    01141
    -4.29%

    CMBC Capital Announces Executive Resignation

    CMBC Capital Holdings Limited (HK:1141) announced the resignation of Mr. Ng Hoi Kam from his positions as executive director, deputy general manager, and committee member, effective October 24, 2025. His departure is amicable, with no reported disagreements. The board expressed gratitude for his contributions. The latest analyst rating for HK:1141 is a Hold with a price target of HK$1.50. CMBC Capital focuses on capital management and investment services and is listed on the Hong Kong Stock Exchange with a market cap of HK$1.4B.

    Tip Ranks·
    HK
    01141
    -4.29%
    Tip Ranks·
    HK
    01141
    -4.29%

    CMBC Capital Updates Board of Directors and Committee Roles

    CMBC Capital Holdings Limited (HK:1141) has updated its Board of Directors, detailing the roles of each member and the composition of six Board committees. This move underscores the company's commitment to transparency and governance, which may influence its strategic direction. The latest analyst rating for HK:1141 is a Hold with a price target of HK$1.50. The current market cap is HK$1.4B, with an average trading volume of 902,662 shares.

    Tip Ranks·
    HK
    01141
    -4.29%
    Tip Ranks·
    HK
    01141
    -4.29%

    CMBC Capital Holdings Files Updated Director List with HKEX

    CMBC Capital Holdings Ltd. has submitted an updated director list to the Hong Kong Stock Exchange. The Board includes Executive Directors Mr. Li Baochen (Chairman) and Mr. Li Ming; Non-executive Directors Ms. Wu Yuan and Mr. Xu Feng; and Independent Non-executive Directors Mr. Lee, Cheuk Yin Dannis, Mr. Wu Bin, and Mr. Wang Lihua. Key committee roles are outlined, with Mr. Li Baochen leading the Executive and Strategic Development Committees, and Mr. Lee heading the Audit Committee.

    Reuters·
    HK
    01141
    -4.29%
    Reuters·
    HK
    01141
    -4.29%
    © 2025 Longbridge｜Disclaimer